Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy
Taiwan60 participantsStarted 2017-07-01
Plain-language summary
In the current study, we use extracorporeal low-intensity shockwave therapy (ESWT) to treat on patients with type 2 diabetes in stage 3-4 chronic kidney disease and see whether it can improve the proteinuria, renal function, and blood pressure compared to baseline and control group.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \>18 y/o or \<80 y/o
✓. Diagnosed as type 2 diabetes.
✓. Baseline HbA1C \<7.5%
✓. Baseline glomerular filtration rate (eGFR) ≧15 and \<60 ml/min/1.73m2
✓. Baseline urine albumin-to-creatinine ratio (UACR) \>30 and \<3000 mg/g
✓. Subject receives ACEi or ARB for 3 months before enrollment
✓. Subject is willing to sign the permit and receive 12 times shockwave therapy
Exclusion criteria
✕. Subject is pregnant or breast feeding
✕. Subject has cancer or chronic inflammatory disease